- Home
- ONCO vs ADTX Comparison
ONCO vs ADTX Comparison
Compare ONCO & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | ADTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.3K | 641.6K |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONCO | ADTX |
|---|---|---|
| Price | $0.72 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.3M | 1.2M |
| Earning Date | 06-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.80 | ★ 62.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $815,371.00 | $3,195.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.05 |
| 52 Week High | $7.65 | $7.13 |
Technical Indicators
Market Signals| Indicator | ONCO | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 31.49 |
| Support Level | $0.62 | $0.05 |
| Resistance Level | $0.95 | $1.11 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 18.86 | 7.57 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.